MENTHA PIPERITA FLOWER/LEAF OIL.

Key findings

1. 01 Mentha Piperita Oil, when tested at an 8% concentration using a maximization protocol, was not identified as a sensitizer.
2. 02 A water/ethanol extract of Mentha Piperita Leaf demonstrated no skin irritation potential in an in vitro human epidermis model at concentrations of 10% and 100%.
3. 03 Both peppermint essential oil and extracts have shown efficacy in reducing inflammation by inhibiting pro-inflammatory cytokines in vitro and mitigating paw edema in vivo.
4. 04 High concentrations (>90%) of peppermint oil significantly decreased the viral titers of both HSV-1 and HSV-2.

Stability

Formulations incorporating peppermint oil require careful stability assessments, as the pH value may fluctuate during storage. Terpenes inherent in peppermint oil can undergo polymerization upon oxidation, potentially compromising product stability, particularly in fragrance applications.

Synergies

• Menthol, a primary constituent, can enhance the transdermal delivery of other active ingredients in the formulation.

Conflicts

• Should be avoided in individuals with cardiac fibrillation or glucose-6-phosphate dehydrogenase deficiency.
• Formulators must exercise caution when combining with ingredients whose safety is dependent on limited skin absorption, as peppermint oil can increase their penetration.
• The cumulative concentration of shared constituents, such as pulegone, from multiple botanical ingredients in a single formulation must be monitored to prevent reaching hazardous levels.